Native forearm fistulas utilizing the basilic vein: an underused type of vascular access

BACKGROUND: Arteriovenous fistulas (AVFs) are the solution of choice among diverse types of vascular access. The forearm basilic vein is rarely used for creating autogenous vascular access. Its use presents a valuable option when autogenous wrist radial-cephalic direct access cannot be created due to the destruction of forearm veins. Results obtained with autogenous wrist ulnar-basilic direct access and autogenous wrist radial-basilic transposition are presented below. METHODS: In the decade 1993-2003, native fistulas utilizing the forearm basilic vein were performed in 27 patients (14 women, 13 men). The basilic vein was anastomosed to the ulnar artery or was transposed and anastomosed to the radial artery. RESULTS: AVF creation was successful in 22 patients (81.5%). The primary patency rate was 70.4% after 1 year, 61.6% after 2 years and 48.4% after 3 years. CONCLUSIONS: AVFs utilizing the forearm basilic vein can be considered for primary or secondary vascular access because of the acceptable survival rate and low incidence of hand ischemia. Transposition of the basilic vein is a valuable option in the reconstruction of a thrombosed or stenosed radial-cephalic fistula.     

Arteriovenous fistula reconstruction in patients with kidney allograft failure

Abstract: Background:  Kidney recipients with failing allograft function face the vascular access problem again before returning to hemodialysis. An autologous arteriovenous fistula (AVF), according to the recent Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, is the optimal vascular access and the use of prosthetic grafts and catheters should be limited. The objective of this study was to assess the feasibility of AVF reconstruction in patients reentering hemodialysis after kidney allograft failure.
Materials and methods:  Two hundred and forty-one transplant recipients reentered hemodialysis between 1990 and 2005. Before kidney transplantation, 221 patients had a functioning AVF on the forearm. Fistula reconstruction was attempted in 112 (51%) patients because of AVF thrombosis. Three strategies were applied according to forearm vein patency: a new radial-cephalic fistula, a radial-perforating vein fistula, or a radial-basilic forearm transposition was created.
Results:  Forearm AVFs were successfully reconstructed in 85 of the 112 patients (73%). The primary patency of the reconstructed AVFs was 57.6% and 44% at 12 and 24 months. Secondary patency was 64.9% and 54.9% at 12 and 24 months, respectively.
Conclusions:  The reconstruction of an old, thrombosed AVF is possible in kidney recipients returning to dialysis, even if the time from thrombosis to fistula repair is a few years.     

前臂远端贵要静脉转位建立自体血管内瘘手术

目的 探讨前臂远端贵要静脉转位建立自体血管内瘘的方法.方法 自2007年12月至2009年12月我们对26例维持性血液透析患者进行前臂远端贵要静脉转位建立自体血管内瘘手术治疗.26例中有17例为原桡动脉-头静脉内瘘因并发症失去功能,9例初次行血管内瘘手术.手术方式采用贵要静脉转位与肱动脉端侧吻合;贵要静脉转位与桡-动脉端端吻合;贵要动脉与尺动脉端侧或端端吻合,吻合口直径为5.0～8.0 mm.结果 26例患者中有1例因术后血肿压迫闭塞,2例因术后内瘘成熟不良,其余手术患者一次取得成功,术后血流量达200～350 ml/min.对患者的心功能未造成不良影响,也未出现严重并发症.结论 只要适应证选择合适,前臂远端贵要静脉转位建立自体血管内瘘手术,是尽量利用自身血管条件,建立内瘘的一种行之有效的方法.     

Improvements in dialysis access survival with increasing use of arteriovenous fistulas in a Veterans Administration medical center

BACKGROUND: Native arteriovenous fistulas (AVFs) have been found to exhibit higher survival rates and lower complication rates than prosthetic grafts (AVGs). METHODS: Between August 2001 and December 2003, 93 patients with end stage renal disease (ESRD) had primary dialysis access placed at a single Veterans Administration medical center. Of these 93 patients, 67 had AVFs created and 26 patients had AVGs implanted. RESULTS: The percentage of patients who did not require additional intervention was 84% (56 of 67) for AVF and 78% (21 of 26) for AVG after 4 to 31 months of follow-up evaluation. In the AVF group, repeat interventions were as follows: collateral ligation (4), angioplasty owing to central stenosis (2), AVF ligation due to arterial steal phenomenon (1), and new AVF creation owing to clotting (1). Four AVFs were later converted to AVG. In the AVG group there were 4 venous anastomosis stenosis seen in 3 patients who required angioplasty. Two patients needed thrombectomy and revision, and 1 graft was removed because of infection. AVF prevalence in our dialysis patients was 63%, with 33% AVG and 4% temporary catheter. CONCLUSIONS: The National Kidney Foundation-Dialysis Outcome Quality Initiative (NKF-DOQI) guidelines for dialysis access reawakened interest in maximizing the use of renal veins for AVF. AVFs created by using the patient's native vein provides the best vascular access for dialysis when compared with prosthetic grafts. AVF has better long-term patency with fewer complications.     

Practice patterns in the management of arteriovenous fistula stenosis: a northern Italian survey

BACKGROUND: Clinical practice for stenosis detection and treatment in arteriovenous fistulas (AVFs) varies widely and is largely dictated by local customs and expertise. METHODS: In May 2003, a questionnaire was sent to 32 hemodialysis (HD) facilities in north-eastern Italy, to assess the prevalence of patients with an AVF; the screening criteria for stenosis; the preferred imaging technique; the timing of the intervention and the treatment modality for stenosed and thrombosed AVFs. RESULTS: The response rate was 87%; 2895 prevalent patients were evaluated, 86% with an AVF. All facilities routinely screened for stenosis; the majority relying on clinical assessment (86%), and many on multiple surveillance methods by monitoring dialysis pressures and blood pump flow rate (75-68%), measuring access recirculation (64%), Kt/V (54%) and access blood flow rate (11%). Angiography and Doppler ultrasound were used in equal proportion for imaging. All nephrologists agreed on pre-emptive stenosis correction, 57% taking action on well functioning and 43% on failing AVFs. Forty percent of nephrologists preferred either angioplasty or surgery for pre-emptive stenosis correction, while only 18% used both. Surgery was favored over endovascular techniques (57 vs. 36%) for treating thrombosed AVFs, while only 7% of facilities used both. CONCLUSIONS:Our survey shows that, as in 2003, the vast majority of patients in north-eastern Italy were dialyzed with an AVF. Screening for stenosis was universally adopted, though most facilities relied on clinical examination and surrogate access blood flow rate markers. All nephrologists agreed to pre-emptive stenosis correction, and surgery retained a relevant role in the treatment of stenosed and thrombosed AVFs.     

Outcomes of surgical revision of stenosed and thrombosed forearm arteriovenous fistulae for haemodialysis.

BACKGROUND: Surgery is an established treatment for stenosed and thrombosed forearm arteriovenous fistulae (AVFs), but the literature on its outcome is limited. We report our experience of the surgical repair of stenosis in patent and thrombosed forearm AVFs and evaluate the outcome of two procedures, proximal neo-anastomosis (NEO) vs replacement of the stenosed segment with a polytetrafluoroethylene graft interposition (GI). METHODS: Sixty-four stenosed forearm AVFs underwent surgery, 32 pre-emptively and 32 post-thrombosis. End points of the study were initial success, restenosis and access loss rates. After treatment, AVFs were surveilled for restenosis by measuring access flow quarterly and performing at least one follow-up angiogram. RESULTS: Initial procedural success was 92%; 100% for patent and 84% for thrombosed AVFs. The restenosis rate was 0.189 events/AVF-year for both patent and thrombosed AVFs, while the access loss rate was 0.016 events/AVF-year in patent and 0.148 in thrombosed AVFs. Stenosis was corrected by NEO in 27 AVFs and by GI in 30. The restenosis and access loss rates were 0.151 vs 0.214 and 0.033 vs 0.019 events/AVF-year for NEO vs GI, respectively. At Cox's hazard analysis, no variable was significantly associated with restenosis, while the timing of intervention was the only significant determinant of access loss, repaired clotted accesses carrying an 8.0-fold relative risk of access loss compared with patent AVFs (P=0.048). CONCLUSION: Our study shows that surgery remains a valid option for the pre-emptive repair of stenosis and to salvage clotted forearm AVFs, offering an excellent initial success rate and low restenosis rate. It confirms that it is better to treat stenosis pre-emptively than post-thrombosis (though the restenosis rate appears to be uninfluenced by the timing of intervention) and suggests that GI compares favourably with conventional NEO.     

Impact of reintervention for failing upper-extremity arteriovenous autogenous access for hemodialysis

PURPOSE: Although large published series have described their experience with the management of failed or failing prosthetic arteriovenous grafts for hemodialysis, there are scant data regarding failing arteriovenous fistulae (AVFs). To analyze the management of nonfunctioning or nonmaturing AVFs, we reviewed our experience with salvage procedures for these AVFs. MATERIALS AND METHODS: Of the 474 AVFs placed at our institution in 380 patients between June 1997 and March 2001, 75 revisions were performed in 46 patients (49 AVFs). Ages of these patients ranged from 29 to 94 years (mean, 68 +/- 1.4 years). Diabetic patients comprised 51%, and hypertensive patients comprised 75%. Twenty patients underwent 26 vein patch angioplasties, and 17 patients underwent 24 balloon angioplasties. Four patients required four vein interpositions, and 12 patients underwent 12 revisions of the fistula to a more proximal level. Extended salvage procedures consisted of four turn-downs to the basilic vein for proximal cephalic vein thrombosis or stenosis and five extension bypasses to the axillary or jugular vein for subclavian vein thrombosis. RESULTS: Follow-up ranged from 1 to 31 months (mean, 10 months). The patients who underwent open revisions tended to need fewer subsequent procedures. However, primary patency of the vein patch angioplasty was not significantly better as compared with balloon angioplasty (P = .8) by life table analysis. Patency after revision of a radial cephalic fistula and brachial cephalic fistula were not statistically different. One interposition failed during the follow-up, and one revision to a more proximal level thrombosed during the follow-up. Two of the turn-down procedures had thrombosed at 2 and 11 months. The remaining two turn-down procedures have remained functional at 1 and 24 months. One of the extensions thrombosed at 8 months whereas the other four have remained functional at 1, 6, and 8 months. CONCLUSIONS: Despite the limited follow-up data, this review suggests that simple and extended salvage procedures may allow maturation and add to the life span of AVFs for hemodialysis. In addition, these data suggest an advantage for open techniques as compared with percutaneous techniques but only in terms of requiring fewer subsequent procedures.     

Vascular access and chronic renal failure

From 1976 to 1999 a total of 8,849 surgical procedures for vascular access prior to dialysis were performed in the Department of nephrology at Skopje hospital (Macedonia). Cases included 3,114 native arteriovenous fistula (AVF), 715 arteriovenous shunts and 4,964 temporary or indwelling catheters (4,411 (88.86%) in the femoral vein, 410 (8.26%) in the subclavian vein, 143 (2.88%) in the jugular vein and 56 PTFE vascular grafts). Femoral catheterization is the favoured solution for repeated dialysis (90.50% of the 3,440 procedures for indwelling vascular access). Subcutaneous indwelling catheters were used in 270 (7.90%) cases, with vascular access taking place in either the femoral (99 cases), subclavian (123 cases) or jugular vein (48 cases). Biosynthetic vascular grafts represent only 1.6% of all procedures for vascular access. The number of preventive AVFs has been increasing steadily from 14% in the 1980s to 20.8% in the 1990s and 31.50% in 1999. The majority of preventive AVFs (71.80%) and a large number of other surgical procedures for vascular access (44.40%) are performed in day hospital.     

Arteriovenous fistula aneurysmorrhaphy is associated with improved patency and decreased vascular access abandonment

BackgroundUpper extremity hemodialysis arteriovenous fistulas (AVFs) can become aneurysmal over time due to repeated cannulation and/or outflow steno-occlusive disease. The optimal surgical management of aneurysmal AVFs (aneurysmorrhaphy vs interposition graft) has remained unclear.MethodsWe performed a retrospective review in which current procedural terminology codes were used to screen for patients who had undergone surgical treatment of aneurysmal AVFs between 2016 and 2021 at a single hospital system. The patients were included after a review of the operative reports. The cases were divided by surgical procedure (aneurysmorrhaphy vs interposition graft placement). The patients who had undergone primary AVF ligation or other types of repair were excluded. The primary outcomes were primary assisted and secondary patency, and the secondary outcome was dialysis access abandonment. Multivariable Cox proportional hazards regression was used to test the association between the type of AVF aneurysm repair and the primary and secondary outcomes.ResultsFrom 2016 to 2021, 6951 patients had undergone 16,190 dialysis access procedures. Of these procedures, 381 (2.4%) were related to surgical treatment of an aneurysmal AVF. We excluded 58 primary AVF ligation cases and 20 cases involving other types of repair, leaving 303 cases for analysis. These were divided into two groups: aneurysmorrhaphy (n = 123; 41%) and interposition graft (n = 180; 59%). No differences were found between the groups in male gender (68% vs 63%), hypertension (98% vs 98%), or central stenosis (14% vs 22%). The patients who had undergone aneurysmorrhaphy were younger (median age, 54 years vs 59 years); had had a lower rate of diabetes (41% vs 59%), coronary artery disease (41% vs 58%), and congestive heart failure (41% vs 55%); and were less likely to have undergone upper arm access (72% vs 92%). The median follow-up was 11.1 months (interquartile range, 3.6-25.2 months). No differences were found in the incidence of 30-day wound complications (1% vs 3%) or surgical site infections (4% vs 6%). On multivariable Cox regression, interposition graft placement was associated with the loss of primary assisted patency (adjusted hazard ratio [aHR], 2.42; 95% confidence interval [CI], 1.18-4.95), loss of secondary patency (aHR, 3.10; 95% CI, 1.21-7.94), and abandonment of dialysis access (aHR, 3.07; 95% CI, 1.61-5.87; P < .05 for all) at 2 years.ConclusionsAVF aneurysmorrhaphy was associated with improved primary assisted and secondary patency and decreased abandonment of dialysis access. We suggest using aneurysmorrhaphy when AVF aneurysms are indicated for repair. However, individual factors such as patient comorbidities, AVF anatomy, remaining dialysis access options, and patient preference should be considered when planning the surgical approach.     

Outcomes of upper arm arteriovenous fistulas for maintenance hemodialysis access

HYPOTHESIS: Radiocephalic fistulas for maintenance hemodialysis access are not feasible in all patients with end-stage renal disease. Our aim was to review our experience with 3 types of upper arm arteriovenous fistula (AVF) to ascertain whether they are reasonable alternatives to radiocephalic fistulas and which, if any, have superior performance. PATIENTS AND METHODS: Patient medical records were retrospectively reviewed. The main outcomes were maturation rate, time to maturation, assisted maturation rate, complication rates, reintervention rates, primary and assisted primary patency rates, and effects of comorbidities. RESULTS: Eighty-six patients with end-stage renal disease underwent creation of a brachiocephalic, brachiobasilic, or brachial artery-to-median antecubital vein AVF. Overall, 80% matured, with 23% requiring an intervention to achieve maturity. The mean time to maturation was 3.8 months; 47% had a complication (inability to access, thrombosis, and so on), and 43% required additional interventions. The overall primary patency and assisted primary patency rates at 12 months were 50% and 74%, respectively. Brachiobasilic AVFs not superficialized immediately often needed a second operation. There were no significant differences in patency rates among the 3 AVF types. The AVFs in patients with diabetes took 2 months longer to mature than did those in patients without diabetes. CONCLUSIONS: An upper arm AVF is a reasonable alternative for maintenance hemodialysis access when a radiocephalic AVF is not possible. There are 3 valid options from which to choose to best accommodate each patient's antecubital anatomy. Diabetes may adversely affect outcomes. Our data suggest that brachiobasilic AVFs should be superficialized at the initial procedure, if feasible.     

A Comparison of Cryopreserved Vein Allografts and Prosthetic Grafts for Hemodialysis Access

In hemodialysis patients with insufficient vasculature for creation of a native arteriovenous fistula (AVF), a polytetrafluoroethylene (PTFE) graft is commonly utilized. Because of PTFE complications, our group and others have used cryopreserved cadaver femoral vein allografts (Synergraft [SYN], CryoLife, Marietta, GA) in selected patients. Based on our experience with these allografts, we hypothesized that they were more resistant to thrombosis than PTFE grafts. The purpose of this study was to compare the thrombosis rates of SYN and PTFE grafts in a prospective, randomized fashion. Our study was interrupted when the FDA ordered CryoLife, Inc. to retain certain vascular tissue products, and patient accrual stopped in 2003. Most patients referred for hemodialysis access are evaluated with bilateral, upper extremity Doppler ultrasound. Starting in 2001, those with insufficient vasculature for native AVF were offered randomization into the PTFE or SYN groups. All accesses were placed in the upper extremity, above the elbow. Access patency and complications were recorded, and failure was defined as access removal, abandonment, or replacement of > 50% with a new conduit. Prior to FDA interruption of the study, 27 patients were randomized into each group. Patient characteristics were similar, but there were significantly more males and African-Americans in the SYN group. No significant differences were seen in primary or secondary patency, number of thrombectomies, revisions, or total interventions. Significantly more fistulagrams were performed in the SYN group (p < 0.05). No infections were seen in either group, but 2 aneurysms occurred in the SYN group. Nine (33%) patients in each group died with functioning access. Access failures: In the SYN group, 8 of 27 (30%) failed, with 5 failing from multiple access stenoses unresponsive to balloon angioplasty; in the PTFE group 4 of 27 (18%) failed, with 2 failing from multiple stenoses. In conclusion, for initial hemodialysis access in patients without sufficient vasculature for native AVF, our results do not support the routine use of SYN allografts in the general dialysis population.Presented as a poster at the American Society of Nephrology Thirty-seventh Annual Meeting and Scientific Exposition, St. Louis, MO, October 29, 2004.     

Upper arm arteriovenous fistulas as a reliable access alternative for patients requiring chronic hemodialysis.

The wrist fistula is the access procedure of choice in the hemodialysis patient. However, unavailable or unusable anatomy in this aging population has made them difficult to establish. This study retrospectively compares patency, occlusion, and complication rates of upper arm arteriovenous fistulas (AVFs) as a reliable alternative. Fifty-eight upper arm AVFs were created in 52 patients between February 1995 and August 1997 at Hermann Hospital, affiliated with the University of Texas Health Science Center in Houston, Texas. Fistulas were constructed using the brachial artery (BA) side-to-end (n = 56) or side-to-side (n = 1) with either the cephalic vein (CV; n = 39), transposed basilic vein (TBV; n = 16), or other vein [basilic vein (BV; n = 1), transposed cephalic vein (TCV; n = 1), median cubital vein (MCV; n = 1)]. One-year primary patency rates for upper arm AVFs were 66 per cent, and secondary patency rates were 22 per cent. Flow rates averaged 354.6 mL/minute. Primary and secondary patency rates for fistulas created are: BA-CV (67% and 20%), BA-TBV (63% and 25%), and other upper arm AVFs 66 per cent without revisions. Primary patencies for both BA-CV and BA-TBV fistulas were similar to previously reported studies. Secondary patencies proved to be less effective. Upper arm AVFs should be considered before graft placement when wrist and forearm anatomy does not lend itself to fistula creation.     

Comparison of basilic vein and polytetrafluoroethylene for brachial arteriovenous fistula

Purpose: The aim of this study was to compare patency and complication rates between basilic vein and polytetrafluoroethylene (PTFE) for brachial arteriovenous fistulas (AVF) for long-term hemodialysis.Methods: All basilic vein and PTFE brachial AVF constructed between March 1988 and April 1993 were retrospectively reviewed. After construction of life-tables, log-rank testing was used to compare the primary patency rate of basilic vein AVF (n = 59) with the primary and secondary patency rates of PTFE AVF (n = 47). Complication rates were calculated for each type of fistula and compared by use of chi-squared testing.Results: The primary patency rate for basilic vein AVF (90%) was superior to that of PTFE AVF (70%) at 1 year (p < 0.01), and at 2 years (86% vs 49%, p < 0.001). Complications occurred two and a half times more frequently in the PTFE group than in the basilic vein group (p < 0.05).Conclusions: Basilic vein AVF provided superior patency rates and lower complication rates compared with PTFE AVF. Prospective randomized trials comparing the two fistula types is required to firmly establish the basilic vein AVF as the alternative access procedure of choice after a failed or unconstructable radiocephalic fistula. (J VASC SURG 1994;20:896-904.)     

Inferior vena cava bypass: experimental evaluation of externally supported grafts and initial clinical application

Inferior vena caval obstruction is an unusual but important clinical problem for which adequate treatment previously has not been available. Recently, a polytetrafluoroethylene (PTFE) graft with external rigid spiral supports was developed that appeared particularly applicable to the venous system. In 18 dogs a 15 cm length of Impraflex was placed from the proximal right common iliac vein to the inferior vena cava (IVC) at the level of the renal veins after IVC and right iliac vein interruption. End-to-end and end-to-side iliac vein anastomoses were alternated, with and without distal femoral arteriovenous (AV) fistulas (AVFs). At 2 months, with a distal AV fistula, 11 of 12 (92%) grafts were patent, angiograms demonstrated no evidence of intraluminal clot, and there was no hind limb edema. Following AVF ligation 2 months after graft insertion, 10 grafts remained patent, but five developed some intraluminal thrombus and one of them progressed to complete occlusion. Four months after fistula ligation (6 months after graft insertion) 9 of 12 grafts (75%) remained patent. All six grafts without distal AVF were occluded within 1 week. This procedure was performed on one severely symptomatic patient who had IVC occlusion, and currently the patient shows marked improvement. Thus IVC bypass is possible when an externally supported PTFE prosthesis is complemented by a temporary AVF.     

Longitudinal comparison of dialysis access methods: Risk factors for failure

Purpose: To compare dialysis access patency rates and identify risk factors for failure. Methods: All access procedures at our institution from 1987 to 1996 were reviewed. Primary procedures were surgically implanted dual-lumen central venous hemodialysis catheters (SIHCs), peritoneal dialysis catheters (PDCs), arteriovenous fistulas (AVFs), and prosthetic shunts (PTFEs). Results: Five hundred eighty-five primary procedures (236 PTFEs, 87 AVFs, 112 SIHCs, and 150 PDCs) and 259 secondary procedures (215 PTFEs, 14 AVFs, 0 SIHCs, and 30 PDCs) were performed on 350 patients. By life table analysis, SIHCs exhibited the lowest primary patency rate (9% at 1 year; p < 0.0001), whereas PDCs had the highest primary patency rate (57% at 1 year; p < 0.02). The primary patency rates of AVFs and PTFEs was similar, with 43% and 41% 1-year patency rates, respectively (p = 0.70). Less-stringent reporting methods would have increased apparent 1-year patency rates by 9% to 41%. With regard to secondary patency, there was no significant difference between PTFEs and PDCs, with 1-year patency rates of 59% and 70%, respectively (p = 0.62), but PTFEs were more frequently revised. In addition, there was no significant difference between AVF and PTFE secondary patency rates, with 1-year patency rates of 46% and 59%, respectively. Early differences in patency rates for AVFs, PTFEs, and PDCs diminished over time, and at 4 years AVFs had the best secondary patency rate (p = 0.6). The most common reasons for access failure were: PTFEs, thrombosis; AVFs, thrombosis and failure to mature; SIHCs, inadequate dialysis; PDCs, infection and inadequate exchange. By regression analysis, a history of a previous unsalvageable PTFE was the only significant risk factor for failure of a subsequent PTFE (p < 0.01), and the risk of graft failure increased exponentially with the number of previous PTFE shunts. Diabetes was the only significant risk factor for failure of PDCs (p < 0.02; odds ratio, 2.0). Conclusions: The patency rate for PTFEs is similar to that for AVFs, but AVFs require fewer revisions. When replacing a failed access graft, the risk of PTFE failure increases with the number of prior unsalvageable PTFE shunts. PDCs have excellent patency rates, but failure rates are doubled in patients with diabetes. Because of poor patency rates and inadequate dialysis flow rates, SIHCs should be avoided when possible. Reporting methods dramatically affect apparent patency rates, and reporting standards are needed to allow meaningful comparisons in the dialysis access literature. (J Vasc Surg 1997;26:1009-19.)     

Arteriovenous fistula construction in the thigh with transposed superficial femoral vein: our initial experience

PURPOSE: The National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines favor autogenous vein for arteriovenous fistulas (AVFs). This report describes our experience constructing AVFs in the lower extremities of selected patients with the superficial femoral vein (SFV). PATIENTS AND METHODS: This is a retrospective analysis of 25 patients who had AVF construction with SFV from March 1998 to July 2000. In all patients upper extremity access had been exhausted. Eighteen (72%) patients were female, 15 (60%) had diabetes, and 14 (56%) were obese (body mass index > 30 kg/m(2)). The SFV was freed from the supragenicular popliteal level to the profunda femoris vein and divided distally. Eighteen (72%) patients had SFV transposition and distal superficial femoral artery reimplantation; 10 veins were banded to reduce the incidence of postoperative steal syndrome. In seven patients (28%) a composite loop fistula was constructed with a deeply buried 4- to 7-mm polytetrafluoroethylene (PTFE) graft proximally and with superficially transposed SFV distally. One of these seven patients had a PTFE above-knee femoral-popliteal bypass graft with banding of the vein at its takeoff from the distal PTFE graft. RESULTS: Mean follow-up was 9.1 months. One patient died before the fistula could be used. Seven patients (28%) experienced major wound complications. Mean ankle/brachial index before operation was 1.03, and after operation it was 0.81 (paired difference [n = 16] = -0.26.) Mean ankle circumference before operation was 19.5 cm, and after operation it was 20.7 cm (paired difference [n = 17] = +0.87.) Cumulative primary fistula patency at 6 and 12 months was 78% and 73%, respectively. Cumulative secondary fistula patency at 6 and 12 months was 91% and 86%, respectively. There were no fistula infections. One patient eventually had an above-knee amputation after experiencing an acute compartment syndrome. Eight patients required a second operation to alleviate a symptomatic steal syndrome. CONCLUSIONS: The SFV is an excellent conduit for vascular access, whether it is transposed or is part of a composite PTFE-SFV fistula. In this series, fistula infection was nonexistent, thrombosis rates were low, and clinical evidence of venous hypertension was minimal. The major impediment to unrestricted use of SFV in constructing AVFs is a high incidence of clinically significant postoperative ischemia requiring reoperation.     

Overcoming barriers to arteriovenous fistula creation and use

National guidelines advocate the placement of arteriovenous fistulas (AVFs) as the preferred vascular access for hemodialysis (HD) patients because of their low complication rate, lower costs, and prolonged patency, once matured. The current Dialysis Outcomes Quality Initiative (DOQI) guidelines aim for an AVF incidence of 50% and a 40% prevalence in the United States. Although patients currently starting dialysis do so at an increasingly older age and with more comorbidity, they should be given every opportunity to receive an AVF. Meeting this challenge is facilitated by a multidisciplinary approach with early referral to the nephrologist in the predialysis period for access planning. Key components of a vascular access program may include the coordination by a dedicated access coordinator and outcome tracking via a prospective database. Preoperative vessel evaluation and careful selection of an appropriate surgical site, along with an experienced surgeon, improve surgical outcomes. Transposed brachiobasilic or other tertiary fistulas should be offered to patients who cannot receive a native radiocephalic or brachiocephalic fistula. The ability to routinely monitor and salvage failing AVFs is important to achieving successful AVF outcomes. Standardized definitions of AVF outcomes are important to allow individual centers and continuous quality assurance (CQA) programs to track and benchmark their outcomes against local and national standards to help them meet recommended targets.     

Bovine carotid artery and expanded polytetrafluroethylene grafts for hemodialysis vascular access

Seventy-six bovine carotid artery heterografts (BCAH) and 100 expanded polytetrafluroethylene (PTFE) grafts were inserted as chronic hemodialysis arteriovenous fistulas. Cumulative patency at 1 year was 70% for the BCAH group and 87% for the PTFE group and at 2 years was 45 and 73%, respectively. Infection accounted for 38% of BCAH failures and none of the PTFE failures. BCAH required twice as many revisions per dialysis month to maintain patency as did the PTFE grafts (0.036 vs 0.019, respectively). Graft configuration and location did not affect patency rates. At present the PTFE grafts appear superior to the BCAH for construction of arteriovenous dialysis fistulas.     

Restoration of acutely thrombosed arterio-venous fistulae by rTPA and percutaneous angioplasty

Acute thrombosis in native arterio-venous fistulae (AVF) results in considerable patient morbidity. Interventional radiology (IR) comprising thrombolysis and percutaneous transluminal angioplasty (PTA) is well established in the management of thrombosed polytetrafluoroethylene (PTFE) grafts. However its role in thrombosed AVF is uncertain. We looked retrospectively at the role of IR in re-establishing blood flow in acutely throm-bosed AVF. Between 1992-2000, 21 episodes of acutely thrombosed AVF in 15 patients (9 females; age range 29-80yrs) were referred for intervention. All fistulae were being used for haemodialysis at the time. Diagnosis was established by angiography and thrombolysis with recombinant tissue plasminogen activator (rTPA) was attempted in all patients. Discrete stenoses when present (n=12) were then treated with PTA and resistant or recurrent stenoses were managed by stent insertion (n=3). Patients were then heparinised for 24 hours. Technical success as defined by radiological patency was achieved in 86% cases. Clinical success i.e. the ability to reuse of the fistula for haemodialysis was achieved in 62% of the interventions, where patency rates at 3 and 6 months were 92% and 69% respectively. Five patients had recurrence of thrombosis >3 months after the primary procedure, 3 had successful reintervention. Minor local bleeding was the only complication. Our retrospective study shows rTPA and PTA is successful in the management of acutely thrombosed AVF. We advocate the routine use of IR as a valuable technique for prolonging the life of native AVF in patients on maintenance haemodialysis.     

Surgical experience with expanded polytetrafluoroethylene (PTFE) as a replacement graft for traumatized vessels.

With the increased nationwide incidence of major vascular injuries, the need for interposition grafting has become quite common in major trauma centers. Despite extensive experience with such injuries, the choice of a substitute conduit remains controversial. Recent studies have demonstrated the potential of expanded polytetrafluoroethylene (PTFE) as a replacement graft for small arteries and veins. The surgical services at the Ben Taub General Hospital began to use PTFE grafts in traumatic vascular wounds approximately 2 years ago. Eight axillary arteries and 12 brachial arteries have had interposition grafting with PTFE prostheses. Eleven patients have required PTFE interposition grafts in repair of traumatized common, superficial, and profunda femoris arteries and common femoral veins; eight patients had reconstruction in the popliteal artery or vein. Three patients had renal artery revascularization procedures following blunt abdominal trauma, three patient had segmental replacement of the superior mesenteric artery following gunshot wounds, and one carotid artery, one iliac vein, and two axillary veins were grafted with PTFE. All patients with segmental repair of axillary, brachial, femoral, and popliteal vessels have maintained good distal pulses and viable extremities. No grafts have thrombosed, nor become infected, in spite of soft-tissue injury encountered at time or repair. In situations requiring interposition graft placement for reestablishment of distal flow in small arteries and veins, PTFE grafts appear to be an acceptable prosthesis.